Leveraging the replication stress response to optimize cancer therapy
E Cybulla, A Vindigni - Nature Reviews Cancer, 2023 - nature.com
High-fidelity DNA replication is critical for the faithful transmission of genetic information to
daughter cells. Following genotoxic stress, specialized DNA damage tolerance pathways …
daughter cells. Following genotoxic stress, specialized DNA damage tolerance pathways …
[HTML][HTML] Cyclin-dependent kinases in DNA damage response
The cyclin-dependent kinase (CDK) family plays a critical role in a variety of signaling
pathways that regulate transcription and cell-cycle progression. Recently, the role of CDKs …
pathways that regulate transcription and cell-cycle progression. Recently, the role of CDKs …
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …
genetic step that complements activation of KRAS in promoting the development and …
Lessons learned from past cyclin-dependent kinase drug discovery efforts
Z Xie, S Hou, X Yang, Y Duan, J Han… - Journal of Medicinal …, 2022 - ACS Publications
Inhibition of cyclin-dependent kinases (CDKs) has become an effective therapeutic strategy
for treating various diseases, especially cancer. Over almost three decades, although great …
for treating various diseases, especially cancer. Over almost three decades, although great …
Osimertinib resistance: molecular mechanisms and emerging treatment options
Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …
From structure modification to drug launch: A systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy
Z Shi, L Tian, T Qiang, J Li, Y Xing, X Ren… - Journal of medicinal …, 2022 - ACS Publications
Herein, we discuss more than 50 cyclin-dependent kinase (CDK) inhibitors that have been
approved or have undergone clinical trials and their therapeutic application in multiple …
approved or have undergone clinical trials and their therapeutic application in multiple …
Targeting protein kinases for the treatment of Alzheimer's disease: recent progress and future perspectives
Z Li, B Yin, S Zhang, Z Lan, L Zhang - European Journal of Medicinal …, 2023 - Elsevier
Alzheimer's disease (AD) is a serious neurodegenerative disease characterized by memory
impairment, mental retardation, impaired motor balance, loss of self-care and even death …
impairment, mental retardation, impaired motor balance, loss of self-care and even death …
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy
T Wu, Z Zhang, G Gong, Z Du, Y Xu, S Yu, F Ma… - European Journal of …, 2023 - Elsevier
CDK9 plays a vital role in regulating RNA transcription and significantly impacts the
expression of short-lived proteins such as Mcl-1 and c-Myc. Thus, targeting CDK9 holds …
expression of short-lived proteins such as Mcl-1 and c-Myc. Thus, targeting CDK9 holds …
Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2
L Schmitt, I Lechtenberg, D Drießen… - Cell Death …, 2024 - nature.com
Meriolin derivatives represent a new class of kinase inhibitors with a pronounced cytotoxic
potential. Here, we investigated a newly synthesized meriolin derivative (termed meriolin 16) …
potential. Here, we investigated a newly synthesized meriolin derivative (termed meriolin 16) …
The evolving pathways of the efficacy of and resistance to CDK4/6 inhibitors in breast cancer
I Gomes, C Abreu, L Costa, S Casimiro - Cancers, 2023 - mdpi.com
Simple Summary Nowadays, the upfront treatment for patients facing a diagnosis of
advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an …
advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an …